Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

An investigation of human beta defensins and cathelicidin expression in patients with pterygium

Poster Details

First Author: R.Karadag TURKEY

Co Author(s):    N. Bayram   S. Oguztuzun   B. Bozer   G. Guler Simsek   C. Rapuano        

Abstract Details

Purpose:

To investigate Human Beta Defensins (HBD) and Cathelicidin expressions in patients with pterygium.

Setting:

Istanbul Medeniyet University School of Medicine

Methods:

In this retrospective consecutive case series, 26 pterygium specimens and 15 normal conjunctival specimens of 15 control subjects were investigated. Expressions of HBD-1, HBD-2, HBD-3 and cathelicidin (LL-37) were assessed by immunohistochemical staining. A brown color in the cytoplasm and/or nuclei of epithelial cells was defined as positive staining for HBDs and LL-37. For each antibody, the intensity of the reaction (negative [-], weak [1], moderate [2] or strong [3]) was determined in order to describe the immunoreactions.

Results:

The median age was 52 years in both groups. There was no significant difference between the groups in terms of age and sex (p=0.583, p=0.355 respectively). Of the 26 pterygium specimens, 15 (57.7%) (14 weak and 1 moderate staining) demonstrated HBD-2 expression while it was not found in any of the control specimens, One of the pterygium (3.8%) and one of the control specimens (6.7%) demonstrated weak staining for HBD-3. HBD-2 expression was significantly higher in the pterygium specimens than in the controls (p=0.002). None of the tissue specimens had positive staining for HBD-1 or LL-37 in both groups (p=1.00).

Conclusions:

We found increased HBD-2 expression in pterygium specimens compared to controls. The HBD-2 expression that might be stimulated by inflammatory cytokines may be related to inflammation and fibro-vascular proliferation and may play a role in pterygium pathogenesis.

Financial Disclosure:

NONE

Back to Poster listing